Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Halobetasol/lidocaine - Citius Pharmaceuticals

Next Previous
Drug Profile

Halobetasol/lidocaine - Citius Pharmaceuticals

Alternative Names: CITI-002; Halo-Lido; Lidocaine/halobetasol

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Citius Pharmaceuticals LLC
  • Developer Citius Pharmaceuticals Inc
  • Class Acetanilides; Anti-inflammatories; Antiallergics; Antipsoriatics; Class Ib antiarrhythmics; Corticosteroids; Local anaesthetics; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Phospholipase A2 inhibitors; Sodium channel antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemorrhoids

Most Recent Events

  • 02 Jan 2024 Citius Pharmaceuticals plans an end of phase II meeting with the US FDA for regulatory and clinical development program for CITI 002 in early 2024
  • 20 Jun 2023 Efficacy and adverse events data from a phase IIb trial in Haemorrhoids released by Citius Pharmaceuticals
  • 17 May 2023 Citius Pharmaceuticals completes a phase IIb trial in Haemorrhoids in USA (NCT05348200)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top